These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27336610)

  • 1. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
    Rajkumar S; Watson IR
    Br J Cancer; 2016 Jul; 115(2):145-55. PubMed ID: 27336610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.
    Griewank KG; Schilling B
    Am J Clin Dermatol; 2017 Jun; 18(3):303-310. PubMed ID: 28229402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.
    He Y; Wang X
    Comput Biol Med; 2023 Dec; 167():107591. PubMed ID: 37875043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.
    Horn S; Leonardelli S; Sucker A; Schadendorf D; Griewank KG; Paschen A
    J Natl Cancer Inst; 2018 Jun; 110(6):677-681. PubMed ID: 29917141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in melanoma.
    Moschos SJ; Pinnamaneni R
    Surg Oncol Clin N Am; 2015 Apr; 24(2):347-58. PubMed ID: 25769717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal Melanoma: Epidemiology, Biology and Treatment.
    Spencer KR; Mehnert JM
    Cancer Treat Res; 2016; 167():295-320. PubMed ID: 26601869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
    Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
    Front Immunol; 2021; 12():629519. PubMed ID: 33746966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma genomics: a state-of-the-art review of practical clinical applications.
    Guhan S; Klebanov N; Tsao H
    Br J Dermatol; 2021 Aug; 185(2):272-281. PubMed ID: 34096042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reviewing the somatic genetics of melanoma: from current to future analytical approaches.
    Dutton-Regester K; Hayward NK
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):144-54. PubMed ID: 22248438
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Huang Y; Lin A; Gu T; Hou S; Yao J; Luo P; Zhang J
    Immunotherapy; 2023 Oct; 15(15):1275-1291. PubMed ID: 37584225
    [No Abstract]   [Full Text] [Related]  

  • 12. UV-induced N-ras mutations are T-cell targets in human melanoma.
    van Elsas A; Scheibenbogen C; van der Minne C; Zerp SF; Keilholz U; Schrier PI
    Melanoma Res; 1997 Aug; 7 Suppl 2():S107-13. PubMed ID: 9578425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies.
    Tímár J; Mészáros L; Ladányi A; Puskás LG; Rásó E
    Cell Immunol; 2006 Dec; 244(2):154-7. PubMed ID: 17433276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology of Melanoma.
    Ostrowski SM; Fisher DE
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):29-56. PubMed ID: 33759772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical bioinformatics in melanoma.
    Cheng PF
    Curr Opin Oncol; 2018 Mar; 30(2):113-117. PubMed ID: 29227308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.
    Lu X; Zhang Q; Wang Y; Zhang L; Zhao H; Chen C; Wang Y; Liu S; Lu T; Wang F; Yan F
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1635-1647. PubMed ID: 29948145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative array-based assay for omics pattern in melanoma.
    Dumitru C; Constantin C; Popp C; Cioplea M; Zurac S; Vassu T; Neagu M
    J Immunoassay Immunochem; 2017; 38(4):343-354. PubMed ID: 28613106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    Kawakami A; Fisher DE
    J Invest Dermatol; 2016 Dec; 136(12):2342-2344. PubMed ID: 27884291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of SDHD promoter mutations in various types of melanoma.
    Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.